[go: up one dir, main page]

PE20081364A1 - Composicion farmaceutica que comprende valsartan - Google Patents

Composicion farmaceutica que comprende valsartan

Info

Publication number
PE20081364A1
PE20081364A1 PE2007001173A PE2007001173A PE20081364A1 PE 20081364 A1 PE20081364 A1 PE 20081364A1 PE 2007001173 A PE2007001173 A PE 2007001173A PE 2007001173 A PE2007001173 A PE 2007001173A PE 20081364 A1 PE20081364 A1 PE 20081364A1
Authority
PE
Peru
Prior art keywords
modifier
pharmaceutical composition
valsartan
composition including
acid
Prior art date
Application number
PE2007001173A
Other languages
English (en)
Inventor
Dieter Becker
Barbara Luckel
Stefanie Siepe
Jorg Ogorka
Bruno Galli
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39047776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081364(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP06120038A external-priority patent/EP1897537A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20081364A1 publication Critical patent/PE20081364A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA SOLIDA, QUE COMPRENDE i) UN COMPUESTO DE FARMACO ACIDO TAL COMO UN ANTAGONISTA DEL RECEPTOR DE ANGIOTENSINA II SIENDO PEREFERIDO VALSARTAN; ii) AL MENOS UN MODIFICADOR DE pH QUE TIENE UN pKa MAYOR DE 2 SIENDO SELECCIONADO DE ACIDO CITRICO, FUMARICO, SUCCINICO, ADIPICO Y MALEICO, DONDE LA PROPORCION PESO/PESO DEL MODIFICADOR DE pH AL FARMACO ACIDO ES ENTRE 0.01:1 Y 10:1; Y iii) AL MENOS UN EXCIPIENTE; ADEMAS COMPRENDE UN POLIMERO DE MATRIZ QUE COMPRENDE HIDROXI-PROPIL-CELULOSA QUE CONTIENE UNA DISPERSION SUSTANCIALMENTE UNIFORME DEL FARMACO ACIDO Y EL MODIFICADOR DE pH. ESTA COMPOSICION SE ADAPTA PARA PROPORCIONAR UN pH MICRO-AMBIENTAL DE 5 O MENOS EN CUANDO MENOS UNA REGION DEL TRACTO GASTRO INTESTINAL; SIENDO UTIL EN EL TRATAMIENTO DE HIPERTENSION, INSUFICIENCIA CARDIACA O INFARTO DE MIOCARDIO
PE2007001173A 2006-09-04 2007-08-29 Composicion farmaceutica que comprende valsartan PE20081364A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06120038A EP1897537A1 (en) 2006-09-04 2006-09-04 Composition comprising an angiotensin II receptor antagonist
EP07103396 2007-03-02

Publications (1)

Publication Number Publication Date
PE20081364A1 true PE20081364A1 (es) 2008-12-04

Family

ID=39047776

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001173A PE20081364A1 (es) 2006-09-04 2007-08-29 Composicion farmaceutica que comprende valsartan

Country Status (5)

Country Link
AR (1) AR062613A1 (es)
CL (1) CL2007002553A1 (es)
PE (1) PE20081364A1 (es)
TW (1) TW200817054A (es)
WO (1) WO2008028885A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0715628D0 (en) * 2007-08-10 2007-09-19 Generics Uk Ltd Solid valsartan composition
WO2014074749A1 (en) * 2012-11-07 2014-05-15 NaZura BioHealth, Inc. Gras enteric coating formulations and methods of making and using same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
ZA991706B (en) * 1998-03-04 2000-10-03 Takeda Chemical Industries Ltd Sustained-release preparation for Aii Antagonist, production and use thereof.
AU2001232348A1 (en) * 2000-02-21 2001-08-27 Takeda Chemical Industries Ltd. Sustained release preparations of physiologically active compound hardly solublein water and production process and use of the same
AU2003225102A1 (en) * 2002-04-23 2003-11-10 Bristol-Myers Squibb Company Modified-release vasopeptidase inhibitor formulation, combinations and method
WO2005089720A1 (en) * 2004-03-10 2005-09-29 Ranbaxy Laboratories Limited Valsartan tablets and the process for the preparation thereof
PL2033629T3 (pl) * 2004-12-24 2013-04-30 Krka Stała kompozycja farmaceutyczna zawierająca walsartan

Also Published As

Publication number Publication date
WO2008028885A2 (en) 2008-03-13
TW200817054A (en) 2008-04-16
AR062613A1 (es) 2008-11-19
WO2008028885A3 (en) 2008-05-02
CL2007002553A1 (es) 2008-05-16

Similar Documents

Publication Publication Date Title
NO20083836L (no) N-hydroksyakrylamidforbindelser
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
AR069554A1 (es) Compuesto triciclico de amino benzoimidazol
IN2012DN02465A (es)
PE20020082A1 (es) Composicion farmaceutica que comprende un inhibidor de aldosterona-sintasa y un antagonista del receptor de angiotensina ii (at1)
NZ592255A (en) Folate receptor binding conjugates of antifolates
AR111570A1 (es) Composición farmacéutica que comprende selexipag
EP2178869A4 (en) INDOL COMPOUNDS AS AN INHIBITORS OF CELL NECROSIS
MX2009004467A (es) Compuestos benzoilo amino heterociclilo como activadores de la glucoquinasa (glk).
WO2007084460A8 (en) Pharmaceutical compositions with enhanced stability
BRPI0809931B8 (pt) antagonistas do receptor do hormônio liberador de gonadotrofina e métodos relacionados com o mesmo
PE20130210A1 (es) Composicion farmaceutica solida que comprende un derivado de bencimidazol y un agente de control de ph
AR047993A1 (es) Composicion farmaceutica que comprende pimobendano
MX2012007603A (es) Macromolecula para el suministro de farmacos de proteina, polipeptido o peptido y un metodo de produccion para la misma, y una composicion de liberacion lenta para farmacos de proteina, polipeptido o peptido y un metodo de produccion para la misma.
PE20061195A1 (es) Derivado de bencimidazol como antagonista de angiotensina ii
CY1112702T1 (el) Βελτιωμενη φαρμακευτικη συνθεση που περιεχει εναν αντισπασμωδικο παραγοντα πυρρολιδονης και μεθοδος για την παρασκευη της
PE20060768A1 (es) Composicion farmaceutica que comprende hidroclorotiazida y telmisartano
EA201201662A1 (ru) Дизамещенные тетрагидрофуранильные соединения в качестве антагонистов брадикининового рецептора в1
ATE478856T1 (de) Spirobenzodioxole und deren verwendung als cb1- antagonisten
NO20080552L (no) GLP-1 farmasoytiske sammensetninger
PE20081364A1 (es) Composicion farmaceutica que comprende valsartan
UA95274C2 (ru) Твердый фармацевтический препарат, содержащий ирбесартан, и способы его изготовления
TW200640933A (en) Anthelmintic compounds
PE20091203A1 (es) Composiciones farmaceuticas que comprende alisquireno o una sal farmaceuticamente aceptable del mismo
WO2007109615A3 (en) β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS

Legal Events

Date Code Title Description
FD Application declared void or lapsed